Eximore Ltd.   Report issue

For profit
Founded: Jerusalem Israel (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2018
NCT03318146
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Eximore Ltd.

Active Ingredients

Drugs in Other Trials (1)

latanoprost (xalatan) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1